Surrogate endpoints, part 1 from definition to meta-analytic framework /

Hämta fulltext
Series

Surrogate endpoints, part 2 further developments /

Hämta fulltext
Series

Randomization, blinding and drug supply in interactive voice response trials

Hämta fulltext
Series

Ecological considerations for gene drive systems

Hämta fulltext
Series

Guidance for responsible testing and implementation of gene-drive systems

Hämta fulltext
Series

Data fusion examples in fusing metabolomics and transcriptomics data /

Hämta fulltext
Series

Bridging our mandates evidence-based practice (EBP) and patient-centered care (PCC), part 1 of 2 /

Hämta fulltext
Series

Clinical research and care in the era of "N-of-1" precision cancer medicine

Hämta fulltext
Series

Bridging our mandates evidence-based practice (EBP) and patient-centered care (PCC), part 2 of 2/

Hämta fulltext
Series

Comparing transcriptomes of distant organisms the comparative ENCODE resource, part 1 of 2 /

Hämta fulltext
Series

Comparing transcriptomes of distant organisms models of gene expression, part 2 of 2 /

Hämta fulltext
Series

Survival analysis

Hämta fulltext
Series

Randomization in N-of-1 clinical trials is it possible to draw causal inferences from single-patient data /

Hämta fulltext
Series

Introduction to systematic reviews for librarians

Hämta fulltext
Series

Teixobactin kills pathogens without detectable resistance

Hämta fulltext
Series (Antibiotic resistance)
Series (Small molecule drug discovery)

Manufacturing viral gene therapy vectors general approaches and challenges /

Hämta fulltext
Series

Clinical proteomics in gastrointestinal cancers

Hämta fulltext
Series

A concept for multi-marker approaches in clinical proteomics

Hämta fulltext
Series

Proteomics in cardiovascular disease clinical considerations /

Hämta fulltext
Series

Application of proteomics in fetal and neonatal medicine

Hämta fulltext
Series